While the jury did not decide in CellTrust’s favor on eight of the 50 claims within the ‘012 and ‘837 patents, CellTrust believes that the results were contrary to and not supported by the evidence and intends to seek available post-verdict relief. CellTrust continues to believe in the strength of its patents and will vigorously enforce its intellectual property rights.

 

For patent licensing please contact: